Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 .
Amarin Corporation plcDecember 13, 2020 GMT
VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data using VASCEPA loading dose
VASCEPA administration resulted in a significant 52% reduction of the total patient-reported symptom outcome prevalence score as compared to a 24% reduction in the usual care group
Larger follow-on clinical studies have commenced of VASCEPA as a therapeutic option in COVID-19 settings, anticipated to be completed in 2021
Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020 – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
National Academy of Inventors names Gordon Freeman a 2020 Fellow
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Mass General Brigham Congratulates Two Leaders Named to Biden-Harris Health Care Team
Mass General BrighamDecember 11, 2020 GMT
Boston, Dec. 11, 2020 (GLOBE NEWSWIRE) Mass General Brigham congratulates the two leading clinicians with deep roots at Mass General Brigham who have been named to President-elect Joe Biden’s health care leadership team. Rochelle Walensky, MD, MPH, Chief of the Infectious Disease Division at Massachusetts General Hospital (MGH) has been named Director of the Centers for Disease Control and Prevention (CDC).
ADVERTISEMENT
“Rochelle is revered by her colleagues and peers and has built a reputation for not only being a world-renowned infectious disease expert, but also for being a deliberate, thoughtful and compassionate leader,” said Anne Klibanski, MD, Mass General Brigham President and Chief Executive Officer. “This is an incredibly proud moment for
(1)
Agendia and Roche evaluate BluePrint s stratification of HER2+ early breast cancer patients treated with adjuvant pertuzumab Agendia, Inc., a world leader in precision oncology for breast cancer, today announced data from the APHINITY trial in a poster spotlight discussion at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020).
The poster, titled
Prediction of benefit from adjuvant pertuzumab by BluePrint RNA sequencing in the APHINITY trial, outlines data from an exploratory analysis of the Phase 3 study that randomized 4,805 patients with histologically centrally confirmed HER2+ early breast cancer into two arms, one which received standard adjuvant chemotherapy and trastuzumab plus pertuzumab, and one which received standard adjuvant chemotherapy and trastuzumab plus placebo, for one year. The analysis was conducted in collaboration with Roche Pharmaceuticals.